Although a trend towards a worse prognosis for patients with PLAGL2-amplified tumors was noticeable—with 5 out of 12 patients with a PLAGL2-amplified tumor being deceased compared to 2 out of 9 patients with a PLAGL1-amplified tumor (Fig. 6b)—PFS and OS did not differ significantly between the two different groups (Fig. 6a, p value = 0.096 and 0.44, respectively). Here, PLAGL1 is linked to neoplasm.